These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 31385130)

  • 1. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
    Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
    Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
    Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.
    Reghunathan M; Kelly KJ; Valasek MA; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2018 Mar; 25(3):702-708. PubMed ID: 29282599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
    Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS
    Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
    Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
    van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
    BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis.
    Masckauchan D; Trabulsi N; Dubé P; Aubé-Lecompte ME; Cloutier AS; Mitchell A; Sideris L
    Surg Oncol; 2019 Mar; 28():69-75. PubMed ID: 30851915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
    Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
    Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.